The landscape of research on B cell and immunotherapy in solid tumors over the past 20 years
Abstract Background Immunotherapy, remarkably immune checkpoint inhibitors, has shown significant efficacy and survival benefits in patients with various solid tumors. Although T lymphocytes have been extensively studied as the primary target cells, the role and application of B cells in solid tumor...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-08-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-03458-3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849226155106762752 |
|---|---|
| author | Shuman Kuang Mingjian Piao Chengjie Li Nan Zhang Jiongyuan Li Shuofeng Li Binhe Tian Lijin Zhao Haitao Zhao |
| author_facet | Shuman Kuang Mingjian Piao Chengjie Li Nan Zhang Jiongyuan Li Shuofeng Li Binhe Tian Lijin Zhao Haitao Zhao |
| author_sort | Shuman Kuang |
| collection | DOAJ |
| description | Abstract Background Immunotherapy, remarkably immune checkpoint inhibitors, has shown significant efficacy and survival benefits in patients with various solid tumors. Although T lymphocytes have been extensively studied as the primary target cells, the role and application of B cells in solid tumor immunotherapy remain less understood. Methods In this study, we conducted a bibliometric analysis of articles on solid tumor immunotherapy related to B cells, published from 2003 to March 28, 2024, in the Web of Science Core Collection. Co-authorship and keyword co-occurrence analyses were performed using VOSviewer, while CiteSpace was used to identify burst keywords and references. Results A total of 1995 publications were analyzed, revealing a year-on-year increase in articles. The most common keywords are “immunotherapy” and “expression”. The most frequently referenced publications focused on tertiary lymphoid structures and B-cell markers. The United States and China are the largest contributors to this field, with Frontiers in Immunology being the most prolific journal. This study provides a comprehensive overview of over 20 years of B cell and immunotherapy research in solid tumors, identifying key countries, institutions, authors, journals, and publications. Conclusions The findings offer valuable insights into the relationship between B cells and immunotherapy in solid tumors. This study primarily unveils the current research hotspots concerning the role of B cells in immunotherapy, encompassing both fundamental research and clinical trials, as well as the accelerating emergence of an increasing number of B-cell-centric immunotherapies. |
| format | Article |
| id | doaj-art-aa2d84360fd844a2a4d47965caab353e |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-aa2d84360fd844a2a4d47965caab353e2025-08-24T11:36:10ZengSpringerDiscover Oncology2730-60112025-08-0116112310.1007/s12672-025-03458-3The landscape of research on B cell and immunotherapy in solid tumors over the past 20 yearsShuman Kuang0Mingjian Piao1Chengjie Li2Nan Zhang3Jiongyuan Li4Shuofeng Li5Binhe Tian6Lijin Zhao7Haitao Zhao8Department of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical UniversityDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeDepartment of Pulmonary and Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeDepartment of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical UniversityDepartment of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeAbstract Background Immunotherapy, remarkably immune checkpoint inhibitors, has shown significant efficacy and survival benefits in patients with various solid tumors. Although T lymphocytes have been extensively studied as the primary target cells, the role and application of B cells in solid tumor immunotherapy remain less understood. Methods In this study, we conducted a bibliometric analysis of articles on solid tumor immunotherapy related to B cells, published from 2003 to March 28, 2024, in the Web of Science Core Collection. Co-authorship and keyword co-occurrence analyses were performed using VOSviewer, while CiteSpace was used to identify burst keywords and references. Results A total of 1995 publications were analyzed, revealing a year-on-year increase in articles. The most common keywords are “immunotherapy” and “expression”. The most frequently referenced publications focused on tertiary lymphoid structures and B-cell markers. The United States and China are the largest contributors to this field, with Frontiers in Immunology being the most prolific journal. This study provides a comprehensive overview of over 20 years of B cell and immunotherapy research in solid tumors, identifying key countries, institutions, authors, journals, and publications. Conclusions The findings offer valuable insights into the relationship between B cells and immunotherapy in solid tumors. This study primarily unveils the current research hotspots concerning the role of B cells in immunotherapy, encompassing both fundamental research and clinical trials, as well as the accelerating emergence of an increasing number of B-cell-centric immunotherapies.https://doi.org/10.1007/s12672-025-03458-3BibliometricsCiteSpaceB cellsImmunotherapyVOSviewerSolid tumor |
| spellingShingle | Shuman Kuang Mingjian Piao Chengjie Li Nan Zhang Jiongyuan Li Shuofeng Li Binhe Tian Lijin Zhao Haitao Zhao The landscape of research on B cell and immunotherapy in solid tumors over the past 20 years Discover Oncology Bibliometrics CiteSpace B cells Immunotherapy VOSviewer Solid tumor |
| title | The landscape of research on B cell and immunotherapy in solid tumors over the past 20 years |
| title_full | The landscape of research on B cell and immunotherapy in solid tumors over the past 20 years |
| title_fullStr | The landscape of research on B cell and immunotherapy in solid tumors over the past 20 years |
| title_full_unstemmed | The landscape of research on B cell and immunotherapy in solid tumors over the past 20 years |
| title_short | The landscape of research on B cell and immunotherapy in solid tumors over the past 20 years |
| title_sort | landscape of research on b cell and immunotherapy in solid tumors over the past 20 years |
| topic | Bibliometrics CiteSpace B cells Immunotherapy VOSviewer Solid tumor |
| url | https://doi.org/10.1007/s12672-025-03458-3 |
| work_keys_str_mv | AT shumankuang thelandscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT mingjianpiao thelandscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT chengjieli thelandscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT nanzhang thelandscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT jiongyuanli thelandscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT shuofengli thelandscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT binhetian thelandscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT lijinzhao thelandscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT haitaozhao thelandscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT shumankuang landscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT mingjianpiao landscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT chengjieli landscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT nanzhang landscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT jiongyuanli landscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT shuofengli landscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT binhetian landscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT lijinzhao landscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years AT haitaozhao landscapeofresearchonbcellandimmunotherapyinsolidtumorsoverthepast20years |